Abcam agrees to be acquired by Danaher in $5.7B deal
Abcam Plc stock (ABCM) was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. (DHR) for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday. Abcam said it expects to remain as a standalone operating company and brand within Danaher's life sciences unit. The deal is expected to close in the middle of 2024. Danaher stock was down by 0.3% in premarket trades.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-28-23 0755ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy